Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC.
Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC.
复制标题
DOI：
10.1371/journal.pone.0054596
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Hofman P
中科院分区：
文献类型：
--
作者：
Sanfiorenzo C;Ilie MI;Belaid A;Barlési F;Mouroux J;Marquette CH;Brest P;Hofman P
由于缺乏特异和可靠的非侵袭性标记物，非小细胞肺癌(NSCLC)的早期诊断以及更好的预后预测在临床上仍然具有挑战性。MicroRNAs(MiRNAs)的发现，特别是在血流中发现的microRNAs，为肿瘤的诊断和预后开辟了新的视角。本研究的目的是确定血浆中特定miRNAs的表达谱是否能够准确区分NSCLC患者和对照组，以及它们是否能够预测可手术切除的NSCLC患者的预后。因此，我们用实时定量(QRT)-聚合酶链式反应技术检测了52例I-IIIA期非小细胞肺癌患者、10例慢性阻塞性肺疾病(COPD)患者和20名年龄、性别和吸烟状况相匹配的健康人血浆中17个与NSCLC相关的miRNAs。我们确定了一种可以区分非小细胞肺癌患者和健康受试者的11血浆miRNA板(AuC = 0.879)。六血浆miRNA板能够区分非小细胞肺癌患者和慢性阻塞性肺疾病患者(AuC = 0.944)。此外，我们发现了三个miRNA血浆信号(高miR-155-5p、高miR-223-3p和低miR-126-3p)，这与腺癌患者的进展风险显著相关。此外，三种miRNA血浆面板(高miR-20a-5p、低miR-152-3p和低miR-199a-5p)显著预测鳞癌患者的生存。总之，我们确定了两种血浆miRNA表达谱，它们可能有助于预测可切除非小细胞肺癌患者的预后。
The diagnosis of non-small cell lung carcinoma (NSCLC) at an early stage, as well as better prediction of outcome remains clinically challenging due to the lack of specific and robust non-invasive markers. The discovery of microRNAs (miRNAs), particularly those found in the bloodstream, has opened up new perspectives for tumor diagnosis and prognosis. The aim of our study was to determine whether expression profiles of specific miRNAs in plasma could accurately discriminate between NSCLC patients and controls, and whether they are able to predict the prognosis of resectable NSCLC patients. We therefore evaluated a series of seventeen NSCLC-related miRNAs by quantitative real-time (qRT)-PCR in plasma from 52 patients with I-IIIA stages NSCLC, 10 patients with chronic obstructive pulmonary disease (COPD) and 20-age, sex and smoking status-matched healthy individuals. We identified an eleven-plasma miRNA panel that could distinguish NSCLC patients from healthy subjects (AUC = 0.879). A six-plasma miRNA panel was able to discriminate between NSCLC patients and COPD patients (AUC = 0.944). Furthermore, we identified a three-miRNA plasma signature (high miR-155-5p, high miR-223-3p, and low miR-126-3p) that significantly associated with a higher risk for progression in adenocarcinoma patients. In addition, a three-miRNA plasma panel (high miR-20a-5p, low miR-152-3p, and low miR-199a-5p) significantly predicted survival of squamous cell carcinoma patients. In conclusion, we identified two plasma miRNA expression profiles that may be useful for predicting the outcome of patients with resectable NSCLC.
登录
查看更多内容
影响因子：
64.8
作者：
Lu, J;Getz, G;Golub, TR
通讯作者：
Golub, TR
影响因子：
4.6
作者：
Chirieac, Lucian R.;Flieder, Douglas B.
通讯作者：
Flieder, Douglas B.
影响因子：
3.3
作者：
Dannemann M;Prüfer K;Lizano E;Nickel B;Burbano HA;Kelso J
通讯作者：
Kelso J
DOI：
10.1158/1078-0432.ccr-09-1736
发表时间：
2010-01-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Landi MT;Zhao Y;Rotunno M;Koshiol J;Liu H;Bergen AW;Rubagotti M;Goldstein AM;Linnoila I;Marincola FM;Tucker MA;Bertazzi PA;Pesatori AC;Caporaso NE;McShane LM;Wang E
通讯作者：
Wang E
影响因子：
6.5
作者：
Lawrie, Charles H.;Gal, Shira;Harris, Adrian L.
通讯作者：
Harris, Adrian L.